Arcturus Therapeutics

Arcturus therapeutics is a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines. We have proprietary technologies, validating partnerships, and an experienced team with deep expertise in delivery and RNA-based therapeutics

Placeholder

Arcturus Therapeutics

  • Arcturus Therapeutics and Duke-NUS Medical School Partner to Develop a Coronavirus (COVID-19) Vaccine using STARR™ TechnologyREAD MORE
  • Arcturus Therapeutics Expands Platform with STARR™ TechnologyREAD MORE
  • Arcturus Therapeutics Receives up to $15 Million Commitment from the Cystic Fibrosis FoundationREAD MORE
  • Ultragenyx and Arcturus Therapeutics Expand Existing Research Collaboration and License AgreementREAD MORE
  • Synthetic GenomicsArcturus Therapeutics Announces Strategic Alliance with Synthetic Genomics, Inc. to develop self-amplifying RNA-based vaccines and therapeuticsREAD MORE

LUNAR®-mediated delivery of RNA into cells

LUNAR particles associate with the cell membrane of a target cell of interest and quickly enter the cell via endocytosis.

Upon entering the cytosol, the LUNAR formulations then become trapped in the endosomes.

With increased acidity as the endosome ages, a pH-mediated disruption enables release of the RNA payload following rapid biodegradation of the LUNAR components.

Once release of the RNA into the cytosol occurs, the translational machinery can interact with the RNA and processing and/or trafficking can then take place to make functional protein.

LUNAR® lipid mediated delivery enables delivery of RNA medicines.

News & Events

  • September 8, 2020

    Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences

    • September 8 2020
    • 0
    read more
  • September 4, 2020

    Arcturus Therapeutics Announces Preclinical Publication of its COVID-19 Vaccine Candidate

    • September 4 2020
    • 0
    read more
  • August 18, 2020

    Arcturus Therapeutics Executes Definitive Supply Agreement with the Israeli Ministry of Health

    • August 18 2020
    • 0
    read more
  • August 11, 2020

    Arcturus Therapeutics Announces that it has Initiated Dosing of its COVID-19 STARR™ mRNA Vaccine Candidate, LUNAR-COV19 (ARCT-021) in a Phase 1/2 study

    • August 11 2020
    • 0
    read more
  • August 10, 2020

    Arcturus Therapeutics Announces Second Quarter 2020 Financial Results and Provides a Corporate Update

    • August 10 2020
    • 0
    read more
  • August 6, 2020

    Arcturus Therapeutics Appoints Lance Kurata as Chief Legal Officer

    • August 6 2020
    • 0
    read more
  • August 4, 2020

    Arcturus Therapeutics to Report Second Quarter 2020 Financial Results and Provide Corporate Update on August 10, 2020

    • August 4 2020
    • 0
    read more
  • July 31, 2020

    Arcturus Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

    • July 31 2020
    • 0
    read more
  • July 29, 2020

    Arcturus Therapeutics Announces Pricing of $173.0 Million Public Offering of Common Stock

    • July 29 2020
    • 0
    read more